1. Shaheen N, Ransohoff DF. Gastroesophageal reflux, Barrett's esophagus, and esophageal cancer: scientific review. JAMA 2002;287:1972–81.
2. Jung KW, Talley NJ, Romero Y, et al. Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett's esophagus: a population-based study. Am J Gastroenterol 2011;106:1447–55.
3. Hvid-Jensen F, Pedersen L, Drewes AM, et al. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med 2011;365:1375–83.
4. Solaymani-Dodaran M, Logan RF, West J, et al. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut 2004;53:1070– 4.
5. Bhat S, Coleman HG, Yousef F, et al. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. J Natl Cancer Inst 2011;103:1049–57.
6. Desai TK, Krishnan K, Samala N, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut 2012;61:970– 6.
7. Alcedo J, Ferrandez A, Arenas J, et al. Trends in Barrett's esophagus diagnosis in Southern Europe: implications for surveillance. Dis Esophagus 2009;22:239–48.
8. Spechler SJ, Sharma P, Souza RF, et al. American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology 2011;140:e18-52.
9. Crane SJ, Richard Locke G 3rd, Harmsen WS, et al. The changing incidence of oesophageal and gastric adenocarcinoma by anatomic sub-site. Aliment Pharmacol Ther 2007;25:447–53.
11. Inadomi JM, Sampliner R, Lagergren J, et al. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med 2003;138:176–86.